Company intelligence / Profile preview

Laboratoire Boreaderme Inc.

Québec, Quebec, Canada

Ownership: Private
Development stage: Phase 2

Overview

The company is conducting Phase 2 clinical trials for BOR-15001L7, an open-label study to evaluate its safety profile compared to docosanol 10% for the management of cold sores in people suffering from recurrent herpes labialis. This collaboration with Ecogene 21 was announced in September 2020.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

BOR15001L7

Partnerships

Ecogene 21

Beyond the preview

Go deeper on Laboratoire Boreaderme Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Laboratoire Boreaderme Inc..

Explore the full profile